Background
• Economic evaluation of health interventions in health technology appraisals (HTA) requires the quantification of health-related quality of life (HRQL) as an outcome measure in terms of utilities
• In models developed to assess the cost-utility of cancer interventions, HRQL is traditionally based on disease progression status or by change from baseline by treatment arm
• Advanced melanoma is associated with a significant HRQL burden and substantial impairments of patients' physical and emotional functioning. This is well documented in the literature 1
• The CA184-024 clinical trial compared ipilimumab (Yervoy ® ) 10 mg/kg + dacarbazine (DTIC) versus DTIC alone in previously untreated patients with advanced melanoma. 2 Patients' HRQL was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) 3
• To be able to use HRQL data in cost-utility analysis, HRQL needs to be expressed in a value between 0 (death) and 1 (perfect health). As the EORTC QLQ-C30 does not produce quality of life scores measured on a scale from 0 to 1, mapping to a preference-based measure is required
• In this study, we map from the cancer-specific EORTC QLQ-C30 to a generic, preference-based measure (EORTC-8D) to produce an HRQL weight that falls between 0 and 1, and seek to identify the optimal approach in modelling patient HRQL, with the intention of populating a cost-utility economic model of ipilimumab as first-line treatment in advanced melanoma patients 
Results
• Of the 502 patients randomised in the CA184-024 trial, 495 patients completed at least one EORTC QLQ-C30 questionnaire
• Responses from 18 patients were excluded because they did not complete the questionnaire at baseline
• The summary scale scores of the EORTC QLQ-C30 at baseline ( Figure 1) were comparable between the trial arms for all of the summary scores generated
• 62 (2.38%) observations could not be mapped to EORTC-8D due to missing data for one of the 10 dimensions used in the mapping algorithm. This level of missing data was deemed to be low enough not to warrant imputation of missing values
• Across both arms of the trial, 78% of questionnaire responses occurred within the first 12 weeks of the trial period, and 90% were completed before the end of the maintenance period at Week 48. The latest observation recorded was over 4 years (228 weeks) after baseline (n=1)
• There were 1,537 questionnaire responses prior to progression and 328 responses after progression, after observations for patients for whom progression events were censored were removed
• Patient utility by progression status and treatment group is shown in Table 2 . Progression status was not predictive of patient utility (p≥0.29)
• The correlation coefficients for utility with respect to the continuous, time-dependent variables are presented in Table  3 . The greatest correlation observed was against time to death
• The relationship between patient utility and continuous time to death (Figure 2 ) demonstrates the ceiling effect that was seen across the HRQL observations and the density of observations closer to death
• Table 4 lists the number of observations and the mean utility for each of the time-to-death categories across the whole trial cohort, and demonstrates how utility decreases as patients approach death
• Treatment with ipilimumab 10mg/kg + DTIC (licensed dose is 3mg/kg monotherapy) was associated with a small, nonsignificant decrement to HRQL (coefficient = -0.02, p=0.06), which should account for the treatment-related adverse event burden of ipilimumab, relative to patients receiving DTIC alone (which is associated with an adverse event burden itself)
• A small decrement is therefore applied to patients receiving ipilimumab as there was a trend towards decreased utility, the decrement applied likely overestimates decrement due to the use of a more intense/toxic dosing regimen. The use of this more intense regimen also impacted treatment discontinuation which was higher than seen in ipilimumab monotherapy studies
• The small sample size for the poorest time-to-death category (i.e. <1 month to death) is presumably due to sicker patients being less likely to complete questionnaires as they approach the end of their life
• The coefficient estimates from the mixed-effects model are presented in Table 5 . Summary statistics of the model indicated that regression was significantly predictive of utility (p≤0.001) across the range of time-to-death categories that were defined
• Applying the coefficients from the regression model generated the utility values for each time-to-death category (Table 6) , with and without ipilimumab treatment. These values were incorporated into the cost-utility analysis of ipilimumab as firstline treatment in advanced melanoma
• The utility values were generated to populate a cost-utility model for ipilimumab and it was assumed that the utility estimate for patients whose time to death was more than 12 months (0.886) was applicable to all patients in this range. 6 Given the similarity of this value to general population figures for the same age group (0.80-0.85) and the high mortality rates in advanced melanoma, this assumption seemed reasonable 6 
Regression model
• The results of the exploratory analyses indicated that time to death was most predictive of patient utility, so a mixed-effects model was used to assess the relationship between patient utility and categorical time to death
• The mixed-effects model was appropriate for examining this particular relationship because the HRQL observations are clustered by individual patients. The regression model accounts for correlation between questionnaire responses completed by the same patient as it is formed of two components:
• A fixed effect, which represents the correlation between time to death and utility
• A random effect, which accounts for patient variation within each time-to-death category
• The mixed-effects model was first run using the pooled data across the two arms of the CA184-024 trial. To examine the impact of treatment on patient utility, a variable was then included to indicate whether a patient was receiving active ipilimumab treatment
• Although the a priori expectation was that treatment with ipilimumab would not have a direct impact on quality of life, the inclusion of a treatment variable in the regression allowed differentiation of the adverse event profiles between the arms of the trial
Methods

Data collection
• Patient level data were derived from the CA184-024 trial, in which 502 patients were randomised between the study arms. The baseline characteristics of these patients are described in Table 1 • The EORTC QLQ-C30 questionnaires 4 were scheduled to be completed by patients at baseline and again at Weeks 4, 7, 12, 24, 36, 48 and throughout the remaining follow-up period where possible
• The resulting dataset contained an HRQL observation for each questionnaire completed, clustered based on patient identifiers
• The observations were assessed for consistency and logic and cleaned using the following rules:
-Where the records were labelled in the wrong order, or where there was an obvious error (e.g. British/American date format conflict), these were corrected. If the cause of the inconsistency was not clear, the record was excluded -Patients for whom there was no baseline observation (i.e. where there was no EORTC QLQ-C30 questionnaire completed within 1 week of the initiation of treatment) were excluded because the time of the baseline response was used to determine the time of disease progression and/or death
• The EORTC QLQ-C30 responses at baseline were condensed into symptom and functioning summary scores for comparison using the EORTC QLQ-C30 manual (Figure 1 ) • Questionnaire responses were mapped to the EORTC-8D using the EORTC QLQ-C30 summary scores and mapping algorithm reported by Rowen et al. 5 • The dates of death and progression were calculated from the date of the baseline response and the recorded overall survival and progression-free survival in the trial
• Dates of disease progression were used to determine whether patients were pre-or post-progression at the time of each completed questionnaire
• To examine the impact that disease progression had on the patient HRQL, pre-and post-progression utilities were summarised and compared using a two-tailed Student's t-test. This was done for the trial cohort as a whole and stratified by treatment randomisation group
• The relationships between patient utility and various timedependent variables were also examined. In the first instance, these were tested as continuous variables and included:
-Time from baseline -Time to progression -Time from progression -Time to death
• Where death and progression events were censored for a patient, and thus the time-dependent variables could not be calculated, these patients were removed from the analysis to include only observations for which the timing of events was certain
• Following examination of utility against the continuous variables, time to death, time to progression and time from progression were also examined as categorical variables, divided into 6 ranges: <1, 1-3, 3-6, 6-9, 9-12 and >12 months to/from event. These ranges were determined by the relationships in the trial data and were validated by clinical opinion 
Conclusions
• In this analysis of clinical trial data of previously untreated patients with advanced melanoma, time to death was significantly predictive of patient utility, with progression-and treatment-based approaches not adequately capturing changes in utility
• This is consistent with earlier observations in previously treated melanoma:
-0.61 for < 30 days to death using EORTC-8D -0.83 for ≥ 180 days to death using EORTC-8D -Utility showed a gradual decline with a steep drop 30-60 days before death
• Based upon this analysis the economic model of first-line ipilimumab for advanced melanoma, used to gain recommendation of ipilimumab at first-line by NICE, modelled patient utility using a series of time-to-death categories 7
• When determining modelling approaches to HRQL, it is important to examine and understand the relevant relationships in the data and choose an appropriate methodology
• In the case of the cost-utility analysis of ipilimumab, it appears that progression-based utility modelling is not appropriate, and that time to death is more meaningful in modelling patient utility 8
